EyePoint (STU:PV3B) Cyclically Adjusted PS Ratio: (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PV3B EyePoint Inc STU:PV3B
41 GF Score
Price €10.50
GF Value €0.59
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is EyePoint Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


EyePoint  (STU:PV3B) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


EyePoint Cyclically Adjusted PS Ratio Related Terms


EyePoint Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for EyePoint's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EyePoint Cyclically Adjusted PS Ratio Chart

EyePoint Annual Data
Trend Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.10 1.39 8.85 4.83 11.80

EyePoint Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.94 9.03 11.80 8.23 0.00

STU:PV3B vs OLMA, LXRX, ANRO: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, EyePoint's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EyePoint Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where EyePoint's Cyclically Adjusted PS Ratio falls into.


STU:PV3B
41GF Score
EyePoint Inc STU:PV3B
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EyePoint Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

EyePoint's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, EyePoint's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.005/333.9520*333.9520
=0.005

Current CPI (Jun. 2026) = 333.9520.

EyePoint Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.072 241.428 0.100
201612 1.656 241.432 2.291
201703 0.161 243.801 0.221
201706 0.163 244.955 0.222
201709 0.082 246.819 0.111
201712 0.177 246.524 0.240
201803 0.162 249.554 0.217
201806 0.113 251.989 0.150
201809 0.055 252.439 0.073
201812 0.252 251.233 0.335
201903 0.187 254.202 0.246
201906 0.601 256.143 0.784
201909 0.213 256.759 0.277
201912 0.716 256.974 0.930
202003 0.587 258.115 0.759
202006 0.293 257.797 0.380
202009 1.042 260.280 1.337
202012 0.404 260.474 0.518
202103 0.249 264.877 0.314
202106 0.260 271.696 0.320
202109 0.268 274.310 0.326
202112 0.312 278.802 0.374
202203 0.227 287.504 0.264
202206 0.293 296.311 0.330
202209 0.271 296.808 0.305
202212 0.266 296.797 0.299
202303 0.191 301.836 0.211
202306 0.224 305.109 0.245
202309 0.372 307.789 0.404
202312 0.305 306.746 0.332
202403 0.203 312.332 0.217
202406 0.165 314.175 0.175
202409 0.174 315.301 0.184
202412 0.171 315.605 0.181
202503 0.324 319.799 0.338
202506 0.066 322.561 0.068
202509 0.012 324.800 0.012
202512 0.006 324.054 0.006
202603 0.007 330.213 0.007
202606 0.005 333.952 0.005

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is EyePoint (STU:PV3B) Overvalued in 2026?

Based on GuruFocus' analysis, EyePoint stock appears to be overvalued. The current stock price of €10.50 is trading 1679.7% above its estimated GF Value™ of €0.59. GuruFocus considers EyePoint to be Significantly Overvalued.

Key valuation signals for STU:PV3B:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €0.59 vs. price of €10.50 (1679.7% above fair value)
  • GF Score™: 41/100 with 7 warning signs

No single metric tells the full story. See the STU:PV3B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


EyePoint Business Description

Other Exchanges EYPT:USA
Address 480 Pleasant Street, Suite C-400, Watertown, MA, USA, 02472
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
41GF Score

Get the complete analysis for STU:PV3B

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.50
Price
€0.59
GF Value